Friday July 24, 2026
Section

Miami

DARPA Selects NRx Pharmaceuticals Defense Subsidiary for Contract Negotiations on FDA-Authorized SPARC-TMS Clinical Trial Advancing Mental Health Care
Press Release

DARPA Selects NRx Pharmaceuticals Defense Subsidiary for Contract Negotiations on FDA-Authorized SPARC-TMS Clinical Trial Advancing Mental Health Care

Potential DARPA Award, FDA-Authorized Phase 2/3 Trial, Breakthrough Therapy NRX-101, and Robotic-Enabled TMS Platform

Read Full Story